Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

TRIAL DESIGN: We present a study protocol for a multi-centre, randomised, double-blind, parallel-group, placebo-controlled trial that seeks to test the feasibility, acceptability and effectiveness of a 52-week period of treatment with the first-in-class co-stimulatory blocker abatacept for preventin...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Laith, Mariam, Jasenecova, Marianna, Abraham, Sonya, Bosworth, Aisla, Bruce, Ian N., Buckley, Christopher D., Ciurtin, Coziana, D’Agostino, Maria-Antonietta, Emery, Paul, Gaston, Hill, Isaacs, John D., Filer, Andrew, Fisher, Benjamin A., Huizinga, Thomas W. J., Ho, Pauline, Jacklin, Clare, Lempp, Heidi, McInnes, Iain B., Pratt, Arthur G., Östor, Andrew, Raza, Karim, Taylor, Peter C., van Schaardenburg, Dirkjan, Shivapatham, Dharshene, Wright, Alison J., Vasconcelos, Joana C., Kelly, Joanna, Murphy, Caroline, Prevost, A. Toby, Cope, Andrew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6633323/
https://www.ncbi.nlm.nih.gov/pubmed/31307535
http://dx.doi.org/10.1186/s13063-019-3403-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6633323/
https://www.ncbi.nlm.nih.gov/pubmed/31307535
http://dx.doi.org/10.1186/s13063-019-3403-7

Ejemplares similares